Carl Campos
Impact in
- Genetics top 0.5%
- Glioma Diagnosis and Treatment
- Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Protein Degradation and Inhibitors 2
- Histone Deacetylase Inhibitors Research 2
- PI3K/AKT/mTOR signaling in cancer 2
- Genetics 6
- Glioma Diagnosis and Treatment 6
- Co-authors
- Ingo K. Mellinghoff (15 shared papers)Daniel Rohle (3 shared papers)Craig B. Thompson (2 shared papers)Jason T. Huse (2 shared papers)Adriana Heguy (2 shared papers)Şevin Turcan (1 shared paper)Armida W. M. Fabius (1 shared paper)Chao Lü (1 shared paper)
- Journals
- Clinical Cancer Research (3 papers)Nature Medicine (1 paper)Journal of Clinical Oncology (1 paper)Journal of Nuclear Medicine (1 paper)Nature Chemical Biology (1 paper)
- Partner nations
- United StatesSpainGermany
In The Last Decade
Carl Campos
16 papers receiving 3.2k citations
Carl Campos's Hit Papers
Peers
Comparison fields: 5 of 115
- Genetics 981
- Cancer Research 988
- Biophysics 149
- Molecular Biology 1.6k
- Biomaterials 207
Countries citing papers authored by Carl Campos
This map shows the geographic impact of Carl Campos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Campos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Campos more than expected).
Fields of papers citing papers by Carl Campos
This network shows the impact of papers produced by Carl Campos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Campos. The network helps show where Carl Campos may publish in the future.
Co-authors
The 25 scholars most cited alongside Carl Campos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Hit paper breakdown → | 2012 | 1404 |
| 2 | A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle Hit paper breakdown → | 2012 | 842 |
| 3 | 2013 | 345 | |
| 4 | 2015 | 248 | |
| 5 | 2012 | 115 | |
| 6 | 2014 | 72 | |
| 7 | 2016 | 35 | |
| 8 | 2021 | 33 | |
| 9 | 2021 | 31 | |
| 10 | 2012 | 31 | |
| 11 | 2017 | 24 | |
| 12 | 2018 | 16 | |
| 13 | 2013 | 14 | |
| 14 | 2024 | 7 | |
| 15 | 2018 | 1 | |
| 16 | 2024 | 1 |
About Carl Campos
Carl Campos is a scholar working on Molecular Biology, Genetics, Cancer Research, Oncology and Epidemiology, having authored 16 papers that have together received 3.2k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (6 papers), Cancer Genomics and Diagnostics (2 papers), Protein Degradation and Inhibitors (2 papers), Photoacoustic and Ultrasonic Imaging (2 papers), Histone Deacetylase Inhibitors Research (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Nanoplatforms for cancer theranostics (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). The work is most often cited by research in Genetics (981 citations), Cancer Research (988 citations), Biophysics (149 citations), Molecular Biology (1.6k citations) and Biomaterials (207 citations). Carl Campos has collaborated with scholars based in United States, Spain and Germany. Frequent co-authors include Ingo K. Mellinghoff, Daniel Rohle, Craig B. Thompson, Jason T. Huse, Adriana Heguy, Şevin Turcan, Armida W. M. Fabius, Chao Lü, Patrick S. Ward and Timothy A. Chan. Their work appears in journals such as Clinical Cancer Research, Nature Medicine, Journal of Clinical Oncology, Journal of Nuclear Medicine and Nature Chemical Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.